HCV and the hepatic lipid pathway as a potential treatment target

Article English OPEN
Bassendine, Margaret F. ; Sheridan, David A. ; Felmlee, Daniel J. ; Bridge, Simon H. ; Toms, Geoffrey L ; Neely, R. Dermot G. (2011)
  • Publisher: Elsevier BV
  • Journal: Journal of Hepatology, volume 55, issue 6, pages 1,428-1,440 (issn: 0168-8278)
  • Related identifiers: doi: 10.1016/j.jhep.2011.06.004
  • Subject: Hepatology | A300
    mesheuropmc: lipids (amino acids, peptides, and proteins)

Atherosclerosis has been described as a liver disease of the heart. The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus-host interaction is a continuous co-evolutionary process involving the host immune system and viral escape mechanisms. One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to: update the hepatologist on lipid metabolism; review the evidence that HCV exploits hepatic lipid pathways to its advantage; discuss approaches to targeting host lipid pathways as adjunctive therapy.
  • References (168)
    168 references, page 1 of 17

    [1] Davis RA, Hui Y. George Lyman Duff Memorial Lecture: atherosclerosis is a liver disease of the heart. Arterioscler Thromb Vasc Biol 2001;21:887-898.

    [2] Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS ONE 2009;4:e6579.

    [3] Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 2009;138:30-50.

    [4] Ginsberg HN, Fisher EA. The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J Lipid Res 2009;50:S162-S166.

    [5] Rutledge AC, Su Q, Adeli K. Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly. Biochem Cell Biol 2010;88:251-267.

    [6] Getz GS, Reardon CA. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J Lipid Res 2009;50:S156-S161.

    [7] Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N. Apolipoprotein E knock-out and knock-in mice. atherosclerosis, metabolic syndrome, and beyond. J Lipid Res 2009;50:S178-S182.

    [8] Kypreos KE, Zannis VI. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J 2007;403:359-367.

    [9] van den Elzen P, Garg S, Leon L, Brigl M, Leadbetter EA, Gumperz JE, et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005;437:906-910.

    [10] Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487-495.

  • Related Research Results (2)
  • Metrics
    No metrics available
Share - Bookmark